A fund under China’s SDIC Fund Management Co. has led a RMB500 million (US$72 million) series B funding round in Ascentage Pharma, a Jiangsu province-based biopharmaceutical company dedicated to the discovery of targeted small-molecule cancer therapeutics.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription? Log in
